COX4I1 Antibody

What is COX4I1 and what is its role in cellular energy metabolism?

COX4I1 (Cytochrome c oxidase subunit 4 isoform 1) is a 169-amino acid protein that serves as a critical component of cytochrome c oxidase (COX), the terminal enzyme in the mitochondrial electron transport chain . This nuclear-encoded protein is the largest of 10 distinct subunits that form each COX monomer, which catalyzes the reduction of oxygen to water during oxidative phosphorylation .

The protein contains several important structural elements:

• Mitochondrial transit peptide (amino acids 1-22)

• ATP binding site (amino acid 42 and positions 95-100)

• Multiple subunit interface sequences

COX4I1 functions as a regulatory subunit within the COX complex due to its ATP binding capability . This allows it to optimize respiratory chain function by helping regulate electron transfer from reduced cytochrome c in the intermembrane space to molecular oxygen. The complex creates an electrochemical gradient across the inner mitochondrial membrane that drives ATP synthesis .

How does COX4I1 differ from its isoform COX4I2?

COX4I1 and COX4I2 represent tissue-specific isoforms of the COX4 subunit with distinct functional properties and expression patterns:

These isoforms appear to have evolved to optimize cellular respiration under different conditions. Research has shown that COX4 subunit isoform exchange can result in modulated oxygen affinity and can affect mitochondrial oxidative phosphorylation and redox state . Understanding these differences becomes particularly important when selecting antibodies for specific experimental applications.

What are current research interests surrounding COX4I1 in disease contexts?

Recent research has identified COX4I1 as a novel vulnerability in certain diseases, particularly acute myeloid leukemia (AML) . Key research findings include:

• Cancer metabolism: Using a cell signaling-focused CRISPR screen, COX4I1 was identified as a novel vulnerability in AML, with its depletion hindering leukemia cell proliferation and impacting in vivo disease progression .

• Mitochondrial dysfunction mechanisms: Loss of COX4I1 has been shown to induce mitochondrial stress and ferroptosis, disrupting mitochondrial ultrastructure and oxidative phosphorylation .

• Therapeutic implications: COX4I1 depletion or pharmacological inhibition of Complex IV (using compounds like chlorpromazine) synergizes with venetoclax, providing a potential avenue for improved leukemia therapy .

• Structure-function relationships: CRISPR gene tiling scans coupled with mitochondrial proteomics have helped identify critical regions within COX4I1 essential for leukemia cell survival .

This research highlights COX4I1 as a critical mitochondrial checkpoint with important clinical implications, making it an increasingly important target for antibody-based research techniques.

What criteria should be considered when selecting a COX4I1-specific antibody?

Selecting the appropriate COX4I1 antibody requires careful consideration of several factors:

• Isoform specificity: Ensure the antibody specifically recognizes COX4I1 and not COX4I2. Review validation data demonstrating discrimination between these isoforms .

• Application compatibility: Verify validation for your specific application:

  • Western blot: Has the antibody been tested on mitochondrial fractions?

  • Immunofluorescence: Is there evidence of proper mitochondrial localization?

  • Immunohistochemistry: Has it been validated on fixed tissues with appropriate controls?

• Species reactivity: Many COX4I1 antibodies work across human, mouse, and rat samples, but verification is essential for your model system .

• Epitope information: Understanding which region of COX4I1 the antibody targets is crucial, as it affects detection in specific experimental contexts:

  • N-terminal antibodies may not detect processed mitochondrial forms

  • Antibodies targeting protein interaction domains may be masked in assembled complexes

• Validation robustness: Look for antibodies that have been validated using:

  • Genetic knockout or knockdown controls

  • Multiple detection methods

  • Peptide competition assays

  • Appropriate positive control tissues/cells

• Published record: Consider antibodies with an established record in peer-reviewed literature, particularly for your specific application and experimental system .

How can I validate the specificity of my COX4I1 antibody against COX4I2?

Thorough validation of COX4I1 antibody specificity requires a multi-faceted approach:

• Genetic model testing:

  • Utilize CRISPR-Cas9 mediated knockout models as described in the literature

  • Test antibody on single COX4I1 knockout, COX4I2 knockout, and double knockout cells

  • Signal should disappear only in samples lacking COX4I1

• Overexpression systems:

  • Test antibody performance in cells transfected with COX4I1-FLAG or COX4I2-FLAG constructs

  • Compare signal intensity between wild-type and overexpression cells

  • Cross-validate with anti-FLAG antibodies

• Peptide competition assays:

  • Pre-incubate antibody with synthetic peptides corresponding to unique regions of either COX4I1 or COX4I2

  • COX4I1-specific antibodies should be blocked only by COX4I1 peptides

• Western blot analysis:

  • Run side-by-side comparisons of samples known to express different ratios of the two isoforms

  • Verify that band intensity correlates with expected expression patterns

  • Confirm the expected molecular weight (21-22 kDa for COX4I1)

• Orthogonal methods:

  • Correlate protein detection with mRNA expression data

  • Consider mass spectrometry-based validation in immunoprecipitated samples

This comprehensive validation approach ensures confidence in experimental results and prevents misinterpretation due to antibody cross-reactivity.

What positive controls are recommended for COX4I1 antibody testing?

Appropriate positive controls are essential for validating COX4I1 antibody performance in different applications:

When using these controls, ensure proper sample preparation:

• For Western blot: Include protease inhibitors during lysis

• For IF/IHC: Optimize fixation and antigen retrieval methods

• For all applications: Run parallel negative controls (secondary antibody only, isotype controls)

Additionally, antibody performance should be validated across different dilutions to identify optimal working concentrations for each specific application.

What are the optimal conditions for COX4I1 immunofluorescence microscopy?

Successful immunofluorescence detection of COX4I1 requires careful attention to sample preparation and staining protocols:

• Cell fixation options:

  • Methanol fixation: 100% methanol for 10 minutes at -20°C (validated in NSC-34 cells)

  • Paraformaldehyde fixation: 4% PFA for 15-20 minutes at room temperature followed by 0.1% Triton X-100 permeabilization

• Blocking conditions:

  • 5-10% normal serum (from secondary antibody species) in PBS

  • 1% BSA in PBS with 0.1% Tween-20

  • Incubate for 30-60 minutes at room temperature

• Antibody incubation parameters:

  • Primary antibody concentration: 5-15 μg/mL has been validated

  • Incubation options: 3 hours at room temperature or overnight at 4°C

  • Secondary antibody: Fluorophore-conjugated antibodies appropriate for your imaging system

• Counterstaining recommendations:

  • Nuclear counterstain: DAPI or Hoechst (1-5 μg/mL)

  • Mitochondrial counterstain: MitoTracker dyes for co-localization confirmation

  • Cytoskeletal counterstain: Phalloidin conjugates for cellular context

• Mounting and imaging considerations:

  • Use anti-fade mounting media to prevent photobleaching

  • For optimal resolution of mitochondrial structures, confocal microscopy is recommended

  • Z-stack acquisition helps visualize the complete mitochondrial network

• Controls to include:

  • Omit primary antibody to assess secondary antibody background

  • Include mitochondrial co-markers to confirm localization

  • If available, include COX4I1-depleted samples as negative controls

Following these optimized conditions will help ensure specific detection of COX4I1 and reliable mitochondrial localization patterns.

What protocol recommendations exist for Western blot analysis of COX4I1?

For optimal Western blot detection of COX4I1, the following protocol has been validated in research settings:

• Sample preparation:

  • Total cell lysates: Lyse cells in RIPA buffer containing protease inhibitors

  • Mitochondrial enrichment: Consider differential centrifugation to concentrate mitochondria

  • Protein determination: Use BCA or Bradford assay to standardize loading

• Gel electrophoresis parameters:

  • Protein loading: 10-30 μg total protein per lane

  • Gel concentration: 12-15% polyacrylamide gels provide optimal resolution for the 21-22 kDa COX4I1 protein

  • Running conditions: Standard SDS-PAGE at 120-150V until adequate separation

• Transfer conditions:

  • Membrane: PVDF or nitrocellulose (0.2 μm pore size recommended)

  • Transfer method: Semi-dry or wet transfer systems (60-90 minutes at 100V or 20-25V respectively)

  • Transfer buffer: Standard Towbin buffer with 20% methanol

• Blocking and antibody incubation:

  • Block in 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Primary antibody dilution: Follow manufacturer recommendations (typically 1:500-1:2000)

  • Incubation: 2 hours at room temperature or overnight at 4°C

  • Washing: 3 x 5-10 minutes in TBST

• Detection options:

  • Chemiluminescence: HRP-conjugated secondary antibodies with ECL detection

  • Fluorescence: IR-fluorescent secondary antibodies provide better quantitative results

• Data analysis recommendations:

  • Include loading controls: Citrate synthase for mitochondrial normalization

  • For quantification: Use linear detection range and appropriate software

  • Present data as relative expression normalized to controls

This protocol has been demonstrated to produce reliable and reproducible detection of COX4I1 in various experimental contexts.

How can I optimize immunohistochemical detection of COX4I1 in tissue sections?

Immunohistochemical detection of COX4I1 in tissue sections requires specific optimization for successful visualization:

• Tissue processing considerations:

  • Fixation: 10% neutral buffered formalin for 24-48 hours

  • Processing: Standard dehydration and paraffin embedding

  • Sectioning: 4-6 μm thickness on positively charged slides

• Antigen retrieval optimization:

  • Heat-induced epitope retrieval in basic buffer (pH 9.0) provides optimal results

  • Pressure cooker method: 110-120°C for 10-15 minutes

  • Allow slides to cool gradually to room temperature

• Blocking steps:

  • Endogenous peroxidase: 3% hydrogen peroxide for 10 minutes

  • Protein block: 5-10% normal serum from secondary antibody species

  • Avidin/biotin block: If using biotin-based detection systems

• Antibody parameters:

  • Primary antibody concentration: 10 μg/mL has been validated for paraffin sections

  • Incubation: Overnight at 4°C provides optimal signal-to-noise ratio

  • Detection system: HRP-DAB systems have been successfully validated

• Visualization and counterstaining:

  • DAB development: Monitor under microscope for optimal signal development

  • Counterstain: Hematoxylin provides good nuclear contrast with the brown DAB signal

  • Dehydration and clearing: Standard ethanol and xylene series

• Validation approaches:

  • Positive control: Normal human kidney tissue has been validated

  • Negative controls: Omit primary antibody on serial sections

  • Pattern verification: Confirm mitochondrial localization pattern

For quantitative assessment of COX4I1 expression in tissue samples, consider digital image analysis using appropriate software to measure staining intensity and distribution patterns.

How can COX4I1 antibodies be used to investigate mitochondrial complex assembly?

Investigating mitochondrial complex assembly using COX4I1 antibodies requires sophisticated experimental approaches:

• Blue Native PAGE analysis:

  • Gently solubilize mitochondria using mild detergents (digitonin or n-dodecyl-β-D-maltoside)

  • Separate native complexes by BN-PAGE

  • Perform Western blotting with COX4I1 antibodies to identify assembled complexes

  • Compare with other COX subunit antibodies (COX1, COX2, COX5a, COX6c) to assess assembly state

• Co-immunoprecipitation studies:

  • Use COX4I1 antibodies to pull down interacting partners

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting

  • Compare assembly intermediates under different physiological conditions

• Proximity labeling approaches:

  • Combine with BioID or APEX2 proximity labeling to identify proteins in close proximity to COX4I1

  • Map the assembly neighborhood of COX4I1 within the complex

  • Track dynamic changes in the protein interaction network during assembly

• Pulse-chase assembly analysis:

  • Use inducible expression systems for tagged COX4I1

  • Track incorporation into mature complexes over time

  • Combine with antibodies against other subunits to determine assembly sequence

• Structural perturbation studies:

  • Introduce mutations in key domains of COX4I1 (as identified in CRISPR tiling screens)

  • Use antibodies to assess incorporation into mature complexes

  • Correlate with functional outcomes on enzyme activity

• In situ visualization:

  • Employ super-resolution microscopy with COX4I1 antibodies

  • Perform correlative light and electron microscopy to visualize complex formation

  • Use proximity ligation assays to detect specific subunit interactions

These approaches provide comprehensive insights into the role of COX4I1 in complex IV assembly, with implications for understanding mitochondrial disorders and developing targeted therapeutics.

What methodologies are recommended for studying COX4I1's role in acute myeloid leukemia (AML)?

Recent research has identified COX4I1 as a vulnerability in AML , suggesting several methodological approaches for investigation:

• Expression profiling across AML subtypes:

  • Use COX4I1 antibodies for immunohistochemistry or flow cytometry analysis of patient samples

  • Construct tissue microarrays for high-throughput screening

  • Correlate expression levels with clinical parameters and genetic subtypes

• Functional studies in AML models:

  • Implement CRISPR-Cas9 knockout or knockdown approaches targeting COX4I1

  • Use COX4I1 antibodies to verify depletion efficiency

  • Assess effects on:

    • Proliferation and apoptosis

    • Mitochondrial function (respiration, membrane potential)

    • Sensitivity to oxidative stress and ferroptosis

• Therapeutic response assessment:

  • Monitor COX4I1 expression before and after treatment with venetoclax

  • Investigate the synergistic effects of COX4I1 inhibition with BCL-2 targeting

  • Develop combination treatment protocols based on COX4I1 status

• Mechanistic investigations:

  • Analyze mitochondrial ultrastructure in COX4I1-depleted AML cells

  • Use antibodies to track changes in mitochondrial protein composition

  • Correlate with metabolic profiling and oxidative phosphorylation measurements

• Translational applications:

  • Develop immunohistochemistry protocols for patient stratification

  • Explore COX4I1 as a biomarker for treatment response

  • Combine with other mitochondrial markers for comprehensive assessment

• In vivo studies:

  • Use patient-derived xenograft models with altered COX4I1 expression

  • Track disease progression using appropriate imaging techniques

  • Test combination therapies targeting mitochondrial vulnerabilities

These methodologies provide a comprehensive framework for investigating COX4I1's role in AML pathogenesis and treatment response, potentially leading to novel therapeutic approaches.

How can researchers study COX4I1 isoform switching under hypoxic conditions?

Studying COX4I1-to-COX4I2 isoform switching under hypoxia requires carefully designed experiments:

This experimental framework allows comprehensive investigation of the physiological significance of COX4I1/COX4I2 isoform switching under hypoxic conditions, with important implications for understanding cellular adaptation to oxygen limitation.

What are common issues in COX4I1 Western blotting and their solutions?

Researchers frequently encounter several challenges when performing Western blots for COX4I1:

Additional methodological considerations:

• For optimal resolution, use 12-15% polyacrylamide gels

• Consider gradient gels to better separate closely migrating bands

• When quantifying, ensure the detection system provides a linear dynamic range

How can researchers optimize COX4I1 immunofluorescence when signal is weak?

When facing weak immunofluorescence signals for COX4I1, consider these optimization strategies:

• Fixation method optimization:

  • Compare methanol fixation (-20°C, 10 minutes) with paraformaldehyde fixation (4%, 15-20 minutes)

  • For methanol fixation: ensure ice-cold methanol and rapid processing

  • For paraformaldehyde: try reduced fixation time to prevent epitope masking

• Antigen retrieval enhancement:

  • Test heat-induced epitope retrieval with different buffers:

    • Citrate buffer (pH 6.0)

    • Tris-EDTA (pH 9.0)

    • Commercial retrieval solutions

  • Optimize retrieval time and temperature

• Signal amplification approaches:

  • Implement tyramide signal amplification (TSA) for 10-50x signal enhancement

  • Use biotin-streptavidin systems for signal amplification

  • Try higher primary antibody concentrations (up to 15 μg/mL has been validated)

  • Extend primary antibody incubation to overnight at 4°C

• Permeabilization optimization:

  • Test different permeabilization agents:

    • Triton X-100 (0.1-0.5%)

    • Saponin (0.1-0.3%)

    • Digitonin (25-50 μg/mL) for selective outer membrane permeabilization

  • Optimize permeabilization time to balance antibody access with epitope preservation

• Detection system improvements:

  • Use high-sensitivity fluorophores (Alexa Fluor 488, 555, or 647)

  • Employ confocal microscopy with appropriate filter sets

  • Optimize exposure settings and detector gain

• Specimen preparation refinements:

  • Reduce autofluorescence (sodium borohydride treatment)

  • Use freshly prepared slides

  • Optimize cell density (70-80% confluence ideal)

These systematic approaches should resolve most weak signal issues in COX4I1 immunofluorescence experiments.

What are the best methods for quantifying COX4I1 expression in comparative studies?

For reliable quantitative analysis of COX4I1 expression in comparative studies, implement these methodological best practices:

• Western blot quantification approach:

  • Use infrared fluorescent secondary antibodies for wider linear detection range

  • Include internal controls on each gel for inter-gel normalization

  • Capture images using systems that provide linear signal detection (e.g., Odyssey)

  • Use software that allows background subtraction and normalization

• Immunofluorescence quantification:

  • Standardize all image acquisition parameters:

    • Exposure time, gain, offset

    • Objective and numerical aperture

    • Z-stack parameters

  • Perform quantification on raw, unprocessed images

  • Measure integrated intensity within defined mitochondrial regions

  • Include cell size normalization

• Flow cytometry approach:

  • Standardize permeabilization conditions

  • Use median fluorescence intensity rather than mean

  • Include appropriate isotype controls

  • Perform proper compensation with single-color controls

• Normalization strategies:

  • For whole cell lysates: Normalize to total protein (via stain-free technology)

  • For mitochondrial fractions: Normalize to other mitochondrial proteins (citrate synthase or VDAC)

  • For tissue sections: Use serial sections and consistent region selection

• Statistical considerations:

  • Perform power analysis to determine appropriate sample size

  • Use appropriate statistical tests based on data distribution

  • Report both relative fold changes and absolute values when possible

  • Include all biological and technical replicates in analysis

• Validation approaches:

  • Verify key findings with orthogonal methods

  • Use multiple antibodies targeting different epitopes

  • Correlate protein expression with mRNA levels

Following these quantification guidelines ensures robust and reproducible assessment of COX4I1 expression changes in experimental and clinical studies.

What emerging research directions involve COX4I1 antibodies?

COX4I1 research is evolving rapidly with several promising directions where antibody-based techniques will play crucial roles:

• Clinical biomarker development: COX4I1 expression patterns are being investigated as potential biomarkers in AML and other cancers, with immunohistochemistry protocols being standardized for clinical implementation .

• Mitochondrial dynamics visualization: Super-resolution microscopy combined with COX4I1 antibodies is enabling detailed studies of mitochondrial ultrastructure changes during stress conditions and disease states.

• Therapeutic response monitoring: Measuring COX4I1 expression changes during treatment with venetoclax and other therapies may predict treatment efficacy and help guide personalized treatment approaches .

• Isoform-specific targeting: The development of highly specific tools to distinguish between COX4I1 and COX4I2 is facilitating research into tissue-specific mitochondrial adaptations and potential therapeutic interventions.

• Post-translational modification mapping: New approaches combining COX4I1 antibodies with mass spectrometry are revealing how phosphorylation, acetylation, and other modifications regulate its function in different contexts.

• Single-cell analysis: Adaptation of COX4I1 antibodies for single-cell technologies is providing unprecedented insights into cellular heterogeneity in normal and disease states.

These emerging directions highlight the continued importance of high-quality, well-validated COX4I1 antibodies for advancing both basic research and clinical applications.

How can researchers integrate COX4I1 analysis with broader mitochondrial function studies?

Integrating COX4I1 analysis with comprehensive mitochondrial function assessment provides deeper mechanistic insights:

• Multi-parameter mitochondrial analysis:

  • Combine COX4I1 antibody detection with functional assays of:

    • Oxygen consumption (Seahorse analysis)

    • Membrane potential (TMRM, JC-1 staining)

    • ROS production (MitoSOX, DCF-DA)

    • ATP synthesis (luminescence-based assays)

  • Correlate protein expression with functional parameters

• Comprehensive respiratory chain assessment:

  • Analyze COX4I1 alongside other OXPHOS components:

    • Complex I (NDUFA9)

    • Complex II (SDHA)

    • Complex III (Core 2)

    • ATP synthase subunits

  • Determine whether changes are COX-specific or affect the entire OXPHOS system

• Integrated omics approaches:

  • Combine antibody-based protein detection with:

    • Transcriptomics (RNA-seq for expression patterns)

    • Proteomics (mass spectrometry for global protein changes)

    • Metabolomics (metabolite profiling for functional outcomes)

  • Identify regulatory networks controlling COX4I1 expression and function

• Dynamic live-cell imaging:

  • Use fluorescently-tagged COX4I1 constructs for real-time studies

  • Analyze mitochondrial morphology, distribution, and dynamics

  • Correlate with functional parameters in living cells

• Disease model applications:

  • Apply integrated analysis in disease-relevant models:

    • Neurodegenerative disease models (examining energetic failure)

    • Cancer models (investigating metabolic reprogramming)

    • Aging studies (assessing mitochondrial decline)

  • Connect COX4I1 alterations to disease mechanisms

This integrated approach provides a comprehensive understanding of how COX4I1 functions within the broader context of mitochondrial biology and cellular metabolism.